Avricore Health Inc. (AVCRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -236.57 Thousand CAD | 59.25% |
| 2022 | -580.52 Thousand CAD | 70.58% |
| 2021 | -1.97 Million CAD | -382.32% |
| 2020 | 698.84 Thousand CAD | 9106.26% |
| 2019 | 7591.00 CAD | 108.99% |
| 2018 | -84.44 Thousand CAD | 84.91% |
| 2017 | -559.73 Thousand CAD | -30.94% |
| 2016 | -427.48 Thousand CAD | 84.3% |
| 2015 | -2.72 Million CAD | -821.8% |
| 2014 | -295.37 Thousand CAD | 49.37% |
| 2013 | -583.38 Thousand CAD | -499.08% |
| 2012 | 146.18 Thousand CAD | 1707.29% |
| 2011 | -9095.00 CAD | 93.8% |
| 2010 | -146.7 Thousand CAD | -464.73% |
| 2009 | -25.97 Thousand CAD | 98.94% |
| 2008 | -2.44 Million CAD | -586.94% |
| 2007 | -356.12 Thousand CAD | -1150.45% |
| 2006 | -28.48 Thousand CAD | 60.26% |
| 2005 | -71.66 Thousand CAD | 68.31% |
| 2004 | -226.15 Thousand CAD | -474.92% |
| 2003 | -39.33 Thousand CAD | 71.3% |
| 2002 | -137.07 Thousand CAD | -163.2% |
| 2001 | -52.07 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -555.61 Thousand CAD | 4.87% |
| 2024 Q1 | -584.04 Thousand CAD | -146.88% |
| 2023 Q2 | -432.37 Thousand CAD | 8.54% |
| 2023 FY | -236.57 Thousand CAD | 59.25% |
| 2023 Q4 | -236.57 Thousand CAD | 32.32% |
| 2023 Q3 | -349.53 Thousand CAD | 19.16% |
| 2023 Q1 | -472.75 Thousand CAD | 18.56% |
| 2022 Q2 | -1.4 Million CAD | 22.01% |
| 2022 FY | -580.52 Thousand CAD | 70.58% |
| 2022 Q4 | -580.52 Thousand CAD | 29.98% |
| 2022 Q3 | -829.12 Thousand CAD | 40.97% |
| 2022 Q1 | -1.8 Million CAD | 8.73% |
| 2021 Q2 | -2.25 Million CAD | 11.28% |
| 2021 Q1 | -2.53 Million CAD | -463.0% |
| 2021 Q3 | -2.18 Million CAD | 2.94% |
| 2021 FY | -1.97 Million CAD | -382.32% |
| 2021 Q4 | -1.97 Million CAD | 9.68% |
| 2020 Q1 | 385.66 Thousand CAD | 4980.58% |
| 2020 Q2 | 690.05 Thousand CAD | 78.93% |
| 2020 FY | 698.84 Thousand CAD | 9106.26% |
| 2020 Q3 | 917.53 Thousand CAD | 32.96% |
| 2020 Q4 | 698.84 Thousand CAD | -23.83% |
| 2019 Q1 | -122.08 Thousand CAD | -44.58% |
| 2019 Q2 | -29.12 Thousand CAD | 76.14% |
| 2019 Q3 | -60.18 Thousand CAD | -106.61% |
| 2019 Q4 | 7591.00 CAD | 112.61% |
| 2019 FY | 7591.00 CAD | 108.99% |
| 2018 Q4 | -84.44 Thousand CAD | 71.91% |
| 2018 Q3 | -300.61 Thousand CAD | -722.4% |
| 2018 Q2 | 48.29 Thousand CAD | 123.03% |
| 2018 Q1 | -209.76 Thousand CAD | 62.52% |
| 2018 FY | -84.44 Thousand CAD | 84.91% |
| 2017 Q4 | -559.73 Thousand CAD | -636.24% |
| 2017 FY | -559.73 Thousand CAD | -30.94% |
| 2017 Q3 | -76.02 Thousand CAD | 87.35% |
| 2017 Q2 | -601.01 Thousand CAD | -15.42% |
| 2017 Q1 | -520.72 Thousand CAD | -21.81% |
| 2016 FY | -427.48 Thousand CAD | 84.3% |
| 2016 Q3 | -863.86 Thousand CAD | 28.07% |
| 2016 Q2 | -1.2 Million CAD | 26.13% |
| 2016 Q1 | -1.62 Million CAD | 23.88% |
| 2016 Q4 | -427.48 Thousand CAD | 50.52% |
| 2015 Q4 | -2.13 Million CAD | 2.98% |
| 2015 Q3 | -2.2 Million CAD | 19.15% |
| 2015 Q1 | -2.46 Million CAD | -238.29% |
| 2015 Q2 | -2.72 Million CAD | -10.28% |
| 2015 FY | -2.72 Million CAD | -821.8% |
| 2014 Q2 | -262.39 Thousand CAD | 11.8% |
| 2014 Q4 | -729.83 Thousand CAD | -819.86% |
| 2014 Q1 | -297.5 Thousand CAD | 10.29% |
| 2014 FY | -295.37 Thousand CAD | 49.37% |
| 2014 Q3 | -79.34 Thousand CAD | 69.76% |
| 2013 FY | -583.38 Thousand CAD | -499.08% |
| 2013 Q4 | -331.62 Thousand CAD | 15.84% |
| 2013 Q3 | -394.06 Thousand CAD | 32.45% |
| 2013 Q2 | -583.38 Thousand CAD | -402.85% |
| 2013 Q1 | 192.63 Thousand CAD | 11.22% |
| 2012 Q3 | 126.93 Thousand CAD | 5536.06% |
| 2012 Q1 | 991.97 Thousand CAD | 0.6% |
| 2012 Q2 | -2335.00 CAD | -100.24% |
| 2012 Q4 | 173.19 Thousand CAD | 36.45% |
| 2012 FY | 146.18 Thousand CAD | 1707.29% |
| 2011 FY | -9095.00 CAD | 93.8% |
| 2011 Q4 | 986.08 Thousand CAD | 816.92% |
| 2011 Q3 | 107.54 Thousand CAD | 1282.45% |
| 2011 Q1 | -17.42 Thousand CAD | -6.42% |
| 2011 Q2 | -9095.00 CAD | 47.81% |
| 2010 Q3 | -129.81 Thousand CAD | 11.51% |
| 2010 Q4 | -16.37 Thousand CAD | 87.39% |
| 2010 Q1 | -252.5 Thousand CAD | -6.54% |
| 2010 FY | -146.7 Thousand CAD | -464.73% |
| 2010 Q2 | -146.7 Thousand CAD | 41.9% |
| 2009 Q1 | -1.78 Million CAD | 10.09% |
| 2009 FY | -25.97 Thousand CAD | 98.94% |
| 2009 Q2 | -25.97 Thousand CAD | 98.54% |
| 2009 Q4 | -237.01 Thousand CAD | 0.0% |
| 2008 Q4 | -1.98 Million CAD | 10.26% |
| 2008 Q1 | -2.42 Million CAD | -46.55% |
| 2008 Q3 | -2.2 Million CAD | 9.75% |
| 2008 FY | -2.44 Million CAD | -586.94% |
| 2008 Q2 | -2.44 Million CAD | -1.01% |
| 2007 Q4 | -1.65 Million CAD | -78.71% |
| 2007 Q1 | -2753.00 CAD | -18.21% |
| 2007 Q2 | -356.12 Thousand CAD | -12835.96% |
| 2007 Q3 | -924.76 Thousand CAD | -159.67% |
| 2007 FY | -356.12 Thousand CAD | -1150.45% |
| 2006 Q3 | -29.38 Thousand CAD | -3.16% |
| 2006 Q4 | -2329.00 CAD | 92.07% |
| 2006 Q2 | -28.48 Thousand CAD | -36.57% |
| 2006 Q1 | -20.85 Thousand CAD | 79.94% |
| 2006 FY | -28.48 Thousand CAD | 60.26% |
| 2005 Q2 | -71.66 Thousand CAD | 57.48% |
| 2005 Q3 | -43.75 Thousand CAD | 38.94% |
| 2005 FY | -71.66 Thousand CAD | 68.31% |
| 2005 Q4 | -103.96 Thousand CAD | -137.6% |
| 2005 Q1 | -168.52 Thousand CAD | -184.06% |
| 2004 Q1 | -395.77 Thousand CAD | 30.21% |
| 2004 FY | -226.15 Thousand CAD | -474.92% |
| 2004 Q3 | -108.2 Thousand CAD | 52.15% |
| 2004 Q4 | -59.32 Thousand CAD | 45.17% |
| 2004 Q2 | -226.15 Thousand CAD | 42.86% |
| 2003 Q3 | -114.91 Thousand CAD | -192.14% |
| 2003 Q2 | -39.33 Thousand CAD | -620.31% |
| 2003 FY | -39.33 Thousand CAD | 71.3% |
| 2003 Q4 | -567.08 Thousand CAD | -393.48% |
| 2003 Q1 | -5461.00 CAD | 90.44% |
| 2002 FY | -137.07 Thousand CAD | -163.2% |
| 2002 Q3 | -126.53 Thousand CAD | 0.0% |
| 2002 Q4 | -57.12 Thousand CAD | 54.86% |
| 2001 FY | -52.07 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 110.724% |
| Arrayit Corporation | 1.05 Million USD | 122.411% |
| Atlantic International Corp. | 236.49 Thousand USD | 200.032% |
| Biocept, Inc. | -788 Thousand USD | 69.978% |
| Bioqual, Inc. | -12 Million USD | 98.03% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | 1140.376% |
| DermTech, Inc. | 17.65 Million USD | 101.34% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 99.959% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 96.793% |
| iMD Companies, Inc. | 1.11 Million USD | 121.2% |
| IDenta Corp. | 524.85 Thousand USD | 145.074% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 103.075% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | -777.749% |
| InVitro International | -313.14 Thousand USD | 24.452% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 115.108% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | -33079.663% |
| Medical Imaging Corp. | 3.79 Million USD | 106.24% |
| NovelStem International Corp. | 3.52 Million USD | 106.718% |
| Optigenex Inc. | 8.93 Million USD | 102.648% |
| PharmChem, Inc. | -1.49 Million USD | 84.17% |
| Proteome Sciences plc | 14.57 Million USD | 101.623% |
| Response Genetics, Inc | -13.08 Million USD | 98.192% |
| Rennova Health, Inc. | 14.82 Million USD | 101.595% |
| RushNet, Inc. | 4.8 Million USD | 104.928% |
| ScreenPro Security Inc. | 135.58 Thousand USD | 274.477% |
| Stella Diagnostics Inc. | 6.19 Million USD | 103.82% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 113.258% |
| Todos Medical Ltd. | 38.31 Million USD | 100.617% |